Birdshot Chorioretinitis in Patients Aged 80 and Older.

Authors :: Debillon L
Thorne JE
Bousquet E
Duraffour P
Kecili S
Monnet D
Brézin AP
Source :: Ocular immunology and inflammation [Ocul Immunol Inflamm] 2024 Sep; Vol. 32 (7), pp. 1212-1217. Date of Electronic Publication: 2023 May 19.
Publication Year :: 2024
Abstract: Purpose: To assess the manifestations of birdshot chorioretinitis (BSCR) in patients aged 80 and over.<br />Design: Among patients with BSCR followed in the CO-BIRD prospective cohort (ClinicalTrials.gov Identifier: NCT05153057), we analyzed the subgroup of patients aged 80 and over.<br />Methods: Patients were assessed in a standardized manner. Confluent atrophy was defined as hypoautofluorescent spots on fundus autofluorescence (FAF).<br />Results: We included 39 (8.8%) of the 442 enrolled CO-BIRD patients. The mean age was 83.8 ± 3.7 years. The mean logMAR BCVA was 0.52 ± 0.76, with 30 patients (76.9%) having 20/40 or better in at least one eye. Thirty-five (89.7%) patients were receiving no treatment. Confluent atrophy in the posterior pole, disrupted retrofoveal ellipsoid zone and choroidal neovascularization were associated with logMAR BCVA >0.3 ( p < .0001).<br />Conclusion: In patients aged 80 and over we observed a striking heterogeneity of outcomes, but most retained a BCVA that allowed them to drive.